 | |
| Industry | Biotechnology |
|---|---|
| Founded | 2005 |
| Headquarters | Chandler's Ford, United Kingdom |
Area served | Worldwide |
Key people | Dr Jim Wicks, Dr Rob Powell and Professor Tom Brown |
| Parent | Novacyt |
| Website | Primerdesign.co.uk |
Primerdesign is a UK-based biotechnology company that designs and sells products for quantitative real-time polymerase chain reaction (qPCR).
Primerdesign was founded in 2005 by Dr Jim Wicks, Dr Rob Powell and Professor Tom Brown within the University of Southampton to focus on PCR and DNA chemistry. The company has grown since then and its products have been used in over 100 countries. The company has a portfolio of over 400 qPCR detection kits and over 9000 research targets. [1]
During the swine flu pandemic in 2009, Primerdesign developed the world's first swine flu detection kit. [2] [3] The kit, which was designed within a fortnight, was designed to give results within two hours. [2] The first shipment of rapid result tests was dispatched to Mexico in April 2009 and is now being used in more than 30 countries. [2]
The company responded to the 2013 meat adulteration scandal by being able to provide qPCR kits to quantitatively measure for horse meat in food. [4] Their kits were used throughout Ireland [5] as well as the UK. [6]
In January 2020 the company launched a molecular test for SARS-CoV-2. [7] [8] [9] [10] The test was approved as eligible for procurement under the World Health Organization's (WHO) Emergency Use Listing process in April 2020, [11] meaning that the test can be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. [12] In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. [13] [14]
Among their product ranges are lines for:
Primerdesign's customers include academic institutions, pharmaceutical companies, independent diagnostic laboratories, hospitals, and official government health agencies.
In 2006, Primerdesign initiated a sponsorship program for PhD students and provide further assistance to the PCR component of their study. [15]
The polymerase chain reaction (PCR) is a method widely used to make millions to billions of copies of a specific DNA sample rapidly, allowing scientists to amplify a very small sample of DNA sufficiently to enable detailed study. PCR was invented in 1983 by American biochemist Kary Mullis at Cetus Corporation. Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993.
Reverse transcription polymerase chain reaction (RT-PCR) is a laboratory technique combining reverse transcription of RNA into DNA and amplification of specific DNA targets using polymerase chain reaction (PCR). It is primarily used to measure the amount of a specific RNA. This is achieved by monitoring the amplification reaction using fluorescence, a technique called real-time PCR or quantitative PCR (qPCR). Combined RT-PCR and qPCR are routinely used for analysis of gene expression and quantification of viral RNA in research and clinical settings.
Taq polymerase is a thermostable DNA polymerase I named after the thermophilic eubacterial microorganism Thermus aquaticus, from which it was originally isolated by Chien et al. in 1976. Its name is often abbreviated to Taq or Taq pol. It is frequently used in the polymerase chain reaction (PCR), a method for greatly amplifying the quantity of short segments of DNA.
QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. European, American, and Asian regional headquarters are located in respectively Hilden, Germany; Germantown, Maryland United States; and Shanghai, China. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer(CEO). The main operative headquarters are located in Hilden, Germany.
A real-time polymerase chain reaction is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR, not at its end, as in conventional PCR. Real-time PCR can be used quantitatively and semi-quantitatively.
New England Biolabs (NEB) produces and supplies recombinant and native enzyme reagents for the life science research, as well as providing products and services supporting genome editing, synthetic biology and next-generation sequencing. NEB also provides free access to research tools such as REBASE, InBASE, and Polbase.
The detection of genetically modified organisms in food or feed is possible by biochemical means. It can either be qualitative, showing which genetically modified organism (GMO) is present, or quantitative, measuring in which amount a certain GMO is present. Being able to detect a GMO is an important part of GMO labeling, as without detection methods the traceability of GMOs would rely solely on documentation.
The history of the polymerase chain reaction (PCR) has variously been described as a classic "Eureka!" moment, or as an example of cooperative teamwork between disparate researchers. Following is a list of events before, during, and after its development:
Multiplex polymerase chain reaction refers to the use of polymerase chain reaction to amplify several different DNA sequences simultaneously. This process amplifies DNA in samples using multiple primers and a temperature-mediated DNA polymerase in a thermal cycler. The primer design for all primers pairs has to be optimized so that all primer pairs can work at the same annealing temperature during PCR.
Recombinase polymerase amplification (RPA) is a single tube, isothermal alternative to the polymerase chain reaction (PCR). By adding a reverse transcriptase enzyme to an RPA reaction it can detect RNA as well as DNA, without the need for a separate step to produce cDNA,. Because it is isothermal, RPA can use much simpler equipment than PCR, which requires a thermal cycler. Operating best at temperatures of 37–42 °C and still working, albeit more slowly, at room temperature means RPA reactions can in theory be run quickly simply by holding a tube. This makes RPA an excellent candidate for developing low-cost, rapid, point-of-care molecular tests. An international quality assessment of molecular detection of Rift Valley fever virus performed as well as the best RT-PCR tests, detecting less concentrated samples missed by some PCR tests and an RT-LAMP test. RPA was developed and launched by TwistDx Ltd., a biotechnology company based in Cambridge, UK.
Cepheid is an American molecular diagnostics company that is a wholly owned subsidiary of Danaher Corporation. Its systems automate traditional nucleic acid tests. The tests can be used to identify and analyze pathogens and genetic disorders. Cepheid sells clinical tests for healthcare-associated infections, infectious diseases, sexual health, oncology and genetics.
Tom Brown FRSC FRSE is a British chemist, biotechnologist, and entrepreneur. He is the Professor of Nucleic acid chemistry at the Department of Chemistry and Department of Oncology at the University of Oxford. Currently, he is serving as the President of the Chemical Biology Interface Division of the Royal Society of Chemistry. He is best known for his contribution in the field of DNA Repair, DNA Click chemistry, and in the application of Molecular genetics in forensics and diagnostics.
The Philippine Genome Center (PGC) is a multi-disciplinary research facility in Quezon City, Metro Manila, Philippines which specializes in genomics.
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main types of tests detect either the presence of the virus or antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.
Kjell Kleppe (1934-1988) was a Norwegian biochemist and molecular biologist who was a pioneer in the PCR technique and built the first laboratory in the country for bio and gene technology. Kjell Kleppe earned a B.S. degree from the University of Oslo (1955-1958) and a Ph.D. in enzymology from the University of Nebraska, USA (1958-1963). Kleppe conducted research at many prestigious universities, including Cambridge and Massachusetts Institute of Technology (MIT), and in 1966, he joined the University of Bergen, where he founded Felleslaboratorium for bioteknologi (FLB), the first gene technology laboratory in Norway with Professor Curt Endresen. He became a member of the European Molecular Biology Organization (EMBO) and Royal Norwegian Society of Sciences and Letters (DKNVS) in 1984.
Truenat is a chip-based, point-of-care, rapid molecular test for diagnosis of infectious diseases. The technology is based on the Taqman RTPCR chemistry which can be performed on the portable, battery operated Truelab Real Time micro PCR platform. Truenat is developed and manufactured by Goa-based Molbio Diagnostics Private Limited.
Seegene, Inc is a Korean manufacturer of in vitro diagnostic (IVD) products, particularly molecular diagnostics. Its portfolio includes a range of assays and screening products for sepsis, respiratory diseases such as influenza and respiratory syncytial virus, as well as sexually transmitted infections (STIs). It was founded in 2000. In early 2020, it began developing and distributing a range of tests for SARS-CoV-2, the virus that causes COVID-19.
The United Kingdom's response to the COVID-19 pandemic consists of various measures by the healthcare community, the British and devolved governments, the military and the research sector.